Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.

Que, Yimei; Xu, Menglei; Xu, Yanjie; Almeida, Varlene Daniela Fernandes; Zhu, Li; Wang, Zhiqiong; Wang, Ying; Liu, Xian; Jiang, Lijun; Wang, Di; Li, Chunrui; Zhou, Jianfeng

Que, Yimei; Xu, Menglei; Xu, Yanjie; Almeida, Varlene Daniela Fernandes; Zhu, Li; Wang, Zhiqiong; Wang, Ying; Liu, Xian; Jiang, Lijun; Wang, Di; Li, Chunrui; Zhou, Jianfeng.

Afiliação

Que Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu M; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Almeida VDF; Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhu L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang Z; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
Wang Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu X; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
Jiang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang D; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
Li C; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhou J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.

Front Immunol ; 12: 755866, 2021.

Article em En | MEDLINE | ID: mdl-34777368

Assuntos

Antígeno de Maturação de Linfócitos B/antagonistas & inibidores; Imunoterapia Adotiva/métodos; Mieloma Múltiplo/terapia; Resultado do Tratamento; Adulto; Idoso; Ensaios Clínicos Fase I como Assunto; Ensaios Clínicos Fase II como Assunto; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Mieloma Múltiplo/mortalidade; Recidiva Local de Neoplasia/terapia; Intervalo Livre de Progressão; Receptores de Antígenos Quiméricos; Estudos Retrospectivos

Palavras-chave

BCMA (TNFRSF17); car-t; extramedullary; multiple myeloma; refractory; relapsed

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Resultado do Tratamento / Antígeno de Maturação de Linfócitos B / Mieloma Múltiplo Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google